← Leaderboards
Anne Valat
Bolden Therapeutics, Inc.
$1,908,521
Attributed
$1,908,521
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $904K · FY2021–24$1M$750K$500K$250K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$1,908,521 · 4
By mechanism
R43$1,408,521 · 3
R41$500,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposNovel StrategiesAgrinNerve Stem CellExperimental StudyNeuromuscular JunctionEfficacy TestingIn VivoMemoryMouse ModelExhibitsEngineeringNeurogenesisDoseKnock-In MouseBone Morphogenetic ProteinsAgedBinding ProteinsNervous System DisorderLearningAdultCognitionAgingPathway Interactions
Grant awards (4)
Preclinical characterization of splice-modifying antisense oligonucleotides targeting neurogenesis in human AD neural cells$504,505
R43 · FY2024 · AG · contact PI
Promoting adult hippocampal neurogenesis using antisense oligonucleotides as an Alzheimer's disease therapy$497,550
R43 · FY2022 · AG · contact PI
Entrepreneurial development award for a novel Alzheimer's disease therapeutic$406,466
R43 · FY2022 · AG · contact PI
Promoting adult hippocampal neurogenesis in Alzheimer's Disease using an antibody-based therapy$500,000
R41 · FY2021 · AG · contact PI